The lawsuit, titled Mazzarino v. ADMA Biologics, Inc., et al., claims that the company and its executives violated federal securities laws by failing to disclose critical information in offering documents. According to the complaint, the firm allegedly utilized channel stuffing to inflate revenue figures and failed to maintain adequate internal controls. Furthermore, the litigation highlights an undisclosed related-party transaction, asserting that these omissions rendered the company's public statements regarding its business operations materially false.
In section Releases
ADMA Biologics Investors Face August 10 Deadline in Securities Lawsuit
Investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status in a pending class action lawsuit. The case, filed in the District of New Jersey, alleges that the company misled shareholders regarding its financial health.
Legal firm Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is representing the class. Investors who suffered financial losses during the specified period are encouraged to contact Managing Partner Lewis Kahn to discuss their options. While the court deadline for requesting appointment as lead plaintiff is August 10, 2026, potential claimants should note that serving as a lead plaintiff is not a requirement to participate in any eventual recovery.
Comments (0)
No comments yet. Be the first!